Key result
In ambulatory heart failure patients, ARB therapy significantly decreased median NT-proBNP levels from 3092.5 pg/ml to 2135.5 pg/ml after 2 months (p=0.003).
Why the study?
Does ARB therapy reduce NT-proBNP levels in ambulatory heart failure patients?
Observational (n=14)
Does ARB therapy reduce NT-proBNP levels in ambulatory heart failure patients?
Answers are grounded in this paper and cite their sources.
ARB therapy significantly reduces NT-proBNP levels in ambulatory heart failure patients after 2 months of treatment, indicating a favorable therapeutic response.
NT-proBNP is an inactive fragment of BNP secreted by stretched ventricle as response to wall stress in patients with heart failure. As a specific cardiac marker, elevated NT-proBNP correlates well with heart failure severity. The principle of heart failure therapy is modulation on neurohormonal activation. ARB can modulate neurohormon on RAA system, that result in decreasing NT-proBNP level and favorable outcomes. Reduction in NT-proBNP more than biologic variability (> 25%) shows a therapy response.This study was to analyze change of NT-proBNP after ARB therapy in ambulatory HF patients. This observational prospective study was carried from September to December 2015. Blood sampling was performed on patients who meet the inclusion criteria of the study at first visit and after 2 months therapy. NT-proBNP was measured by IMMULITE® as primary parameter and creatinin as secondary parameter. There are 14 patients met the inclusion criteria of the study (11 males and 3 females). ARB therapy used in patients were Valsartan (64%), Telmisartan (22%) and Candesartan (14%). After 2 months ARB therapy, a decrease in level of NT-proBNP with initial median 3092.5 (216 – 32112) pg/ml to 2135.5 (350 – 16172) pg/ml respectively were statistically significant (p=0.003). And the secondary parameter creatinin serum convert to eGFR shows a change in eGFR with initial median 73.33 (37.05 – 266.68) ml/minute to 81.04 (39.31 – 167.02) ml/minute respectively were statistically not significant (p=0.657). There were 7 patients (50%) have a decrease > 25%. In this study, we found that ARB therapy can change NT-proBNP level significantly after 2 months therapy.
No takes yet. Share an insight, caveat, or question.
Dewi et al. (2017) conducted an observational in Heart failure (n=14). Angiotensin Receptor Blocker (ARB) therapy was evaluated on Change in NT-proBNP level (p=0.003). In ambulatory heart failure patients, ARB therapy significantly decreased median NT-proBNP levels from 3092.5 pg/ml to 2135.5 pg/ml after 2 months (p=0.003).
Synapse has enriched 10 related papers. Consider them for comparative context: